Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status.

Yanagawa N, Tamura G, Oizumi H, Endoh M, Sadahiro M, Motoyama T.

Anticancer Res. 2011 Apr;31(4):1211-4.

PMID:
21508367
2.

Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.

Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T.

Lung Cancer. 2007 Oct;58(1):131-8.

PMID:
17606310
3.

Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.

Kim H, Kwon YM, Kim JS, Lee H, Park JH, Shim YM, Han J, Park J, Kim DH.

J Clin Oncol. 2004 Jun 15;22(12):2363-70.

PMID:
15197197
4.

Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.

Tomizawa Y, Iijima H, Nomoto T, Iwasaki Y, Otani Y, Tsuchiya S, Saito R, Dobashi K, Nakajima T, Mori M.

Lung Cancer. 2004 Dec;46(3):305-12.

PMID:
15541815
5.

Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.

Kikuchi S, Yamada D, Fukami T, Maruyama T, Ito A, Asamura H, Matsuno Y, Onizuka M, Murakami Y.

Cancer. 2006 Apr 15;106(8):1751-8.

6.

Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.

Kim JS, Kim H, Shim YM, Han J, Park J, Kim DH.

Carcinogenesis. 2004 Nov;25(11):2165-71.

PMID:
15231689
7.

Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers.

Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T.

Cancer Sci. 2003 Jul;94(7):589-92.

8.

Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.

Hsu HS, Chen TP, Hung CH, Wen CK, Lin RK, Lee HC, Wang YC.

Cancer. 2007 Nov 1;110(9):2019-26.

9.
10.

Frequent epigenetic silencing of the FHIT gene in penile squamous cell carcinomas.

Yanagawa N, Osakabe M, Hayashi M, Tamura G, Motoyama T.

Virchows Arch. 2008 Apr;452(4):377-82. doi: 10.1007/s00428-008-0597-6.

PMID:
18299890
11.

Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.

Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, Minna JD, Yokota J.

Clin Cancer Res. 2002 Jul;8(7):2362-8.

12.

Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.

Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar AF.

Cancer. 2004 Apr 1;100(7):1472-7.

13.

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.

Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, Song SY, Han JH, Park CK, Lee JY, Yoo NJ, Lee SH.

Virchows Arch. 2005 May;446(5):483-8.

PMID:
15815931
14.

Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population.

Neyaz MK, Kumar RS, Hussain S, Naqvi SH, Kohaar I, Thakur N, Kashyap V, Das BC, Husain SA, Bharadwaj M.

Biomarkers. 2008 Sep;13(6):597-606. doi: 10.1080/13547500802078859.

PMID:
18608185
15.

Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.

Wu JY, Wang J, Lai JC, Cheng YW, Yeh KT, Wu TC, Chen CY, Lee H.

Ann Surg Oncol. 2008 Nov;15(11):3272-7. doi: 10.1245/s10434-008-0078-9.

PMID:
18712569
16.

Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.

Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ.

Hum Pathol. 2009 Nov;40(11):1534-42. doi: 10.1016/j.humpath.2009.01.029.

PMID:
19695681
17.

Mutation analysis of the FHIT gene in bronchoscopic specimens from patients with suspected lung cancer.

Cecener G, Tunca B, Egeli U, Karadag M, Vatan O, Uzaslan E, Tolunay S.

Tumori. 2008 Nov-Dec;94(6):845-8.

18.

Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.

Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viacava P, Maher ER, Latif F.

Oncogene. 2003 Jan 9;22(1):147-50.

PMID:
12527916
19.

Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.

Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X, Liu D, Hong WK, Mao L.

Cancer Res. 1999 Oct 1;59(19):4798-803.

20.

Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood.

Tan S, Sun C, Wei X, Li Y, Wu Y, Yan Z, Feng F, Wang J, Wu Y.

Exp Lung Res. 2013 May-Jun;39(4-5):182-90. doi: 10.3109/01902148.2013.790096.

PMID:
23614702
Items per page

Supplemental Content

Support Center